Belimumab promising in combination therapy for refractory lupus

doctor and patient
Credit: CC0 Public Domain

For patients with systemic lupus erythematosus (SLE) refractory to conventional treatment, belimumab after rituximab significantly reduces serum immunoglobulin (Ig)G anti-double stranded DNA (dsDNA) levels and the risk for severe flare, according to a study published online Oct. 26 in the Annals of Internal Medicine.

Muhammad Shipa, M.B.B.S., from University College London, and colleagues conducted a phase 2 involving 52 patients with SLE that was refractory to conventional treatment and whose physicians had recommended . Patients were treated with rituximab and then randomly assigned four to eight weeks later to receive intravenous belimumab or placebo for 52 weeks.

The researchers found that IgG anti-dsDNA antibody levels were lower in belimumab-treated patients at 52 weeks compared with placebo-treated patients (geometric mean, 47 versus 103 IU/mL; 70 percent greater reduction from baseline). The risk for severe flare was reduced significantly with belimumab versus placebo (hazard ratio, 0.27), with three and 10 severe flares in the belimumab and placebo groups, respectively. There was no increase seen in the incidence of serious adverse events in the belimumab group.

"These findings support further exploration of belimumab after rituximab as the first combination biologic therapy for with SLE, at least in those whose disease is refractory to conventional therapy and/or requires high corticosteroid dosages," the authors write.

More information: Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Journal information: Annals of Internal Medicine

Copyright © 2021 HealthDay. All rights reserved.

Citation: Belimumab promising in combination therapy for refractory lupus (2021, October 26) retrieved 30 January 2023 from https://medicalxpress.com/news/2021-10-belimumab-combination-therapy-refractory-lupus.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Adding belimumab improves renal outcome in lupus nephritis

2 shares

Feedback to editors